共 128 条
[1]
Beukelman T(2011)2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features Arthritis Care Res (Hoboken) 63 465-482
[2]
Patkar NM(2013)Evaluation of anti-citrullinated type II collagen and anti-citrullinated vimentin antibodies in patients with juvenile idiopathic arthritis Pediatr Rheumatol 11 13-2903
[3]
Saag KG(2016)Anti-cyclic citrullinated peptide antibodies in children with juvenile idiopathic arthritis Electron Physician 8 2891-1530
[4]
Tolleson-Rinehart S(2009)Antibodies to mutated citrullinated vimentin and antibodies to cyclic citrullinated peptides in juvenile idiopathic arthritis Clin Chem Lab Med 47 1525-393
[5]
Cron RQ(2014)Polyarticular juvenile idiopathic arthritis – epidemiology and management approaches Clin Epidemiol 6 379-977
[6]
DeWitt EM(2009)Inactive disease in polyarticular juvenile idiopathic arthritis: current patterns and associations Rheumatology (Oxford) 48 972-724
[7]
Gillima BE(2013)Disease course, outcome, and predictors of outcome in population-based juvenile chronic arthritis cohort followed by 17 years J Rheumatol 40 715-2113
[8]
Chauhan AK(2014)14–3-3η: a novel biomarker platform for rheumatoid arthritis Clin Exp Rheumatol 32 S-35-9-666
[9]
Moore TL(2014)Serum 14-3-3η is a novel marker that complements current serological measurements to enhance detection of patients with rheumatoid arthritis J Rheumatol 41 2104-803
[10]
Hamooda M(2014)14-3-3η is a novel mediator associated with pathogenesis of rheumatoid arthritis and joint damage Arthritis Res Ther 16 R99-1594